BACKGROUND: Studies have shown that community-acquired methicillin-resistant Staphylococcus aureus (MRSA) causes S. aureus skin and soft-tissue infection in selected populations. OBJECTIVE: To determine the proportion of infections caused by community-acquired MRSA, the clinical characteristics associated with community-acquired MRSA, and the molecular epidemiology of community-acquired MRSA among persons with community-onset S. aureus skin and soft-tissue infection. DESIGN: Active, prospective laboratory surveillance to identify S. aureus recovered from skin and soft-tissue sources. SETTING: 1000-bed urban hospital and its affiliated outpatient clinics in Atlanta, Georgia. PATIENTS: 384 persons with microbiologically confirmed community-onset S. aureus skin and soft-tissue infection. MEASUREMENTS: Proportion of infections caused by and clinical factors associated with community-acquired MRSA among persons with community-onset S. aureus skin and soft-tissue infection. Pulsed-field gel electrophoresis and antimicrobial susceptibility patterns were used to epidemiologically classify community-onset S. aureus infections. Community-acquired MRSA was defined by MRSA isolates that either demonstrated a USA 300 or USA 400 pulsed-field type or had a susceptibility pattern showing resistance only to beta-lactams and erythromycin (for isolates not available for pulsed-field gel electrophoresis). RESULTS: Community-onset skin and soft-tissue infection due to S. aureus was identified in 389 episodes, with MRSA accounting for 72% (279 of 389 episodes). Among all S. aureus isolates, 63% (244 of 389 isolates) were community-acquired MRSA. Among MRSA isolates, 87% (244 of 279 isolates) were community-acquired MRSA. When analysis was restricted only to MRSA isolates that were available for pulsed-field gel electrophoresis, 91% (159 of 175 isolates) had a pulsed-field type consistent with community-acquired MRSA; of these, 99% (157 of 159 isolates) were the MRSA USA 300 clone. Factors independently associated with community-acquired MRSA infection were black race (prevalence ratio, 1.53 [95% CI, 1.16 to 2.02]), female sex (prevalence ratio, 1.16 [CI, 1.02 to 1.32]), and hospitalization within the previous 12 months (prevalence ratio, 0.80 [CI, 0.66 to 0.97]). Inadequate initial antibiotic therapy was statistically significantly more common among those with community-acquired MRSA (65%) than among those with methicillin-susceptible S. aureus skin and soft-tissue infection (1%). LIMITATIONS: Some MRSA isolates were not available for molecular typing. CONCLUSIONS: The community-acquired MRSA USA 300 clone was the predominant cause of community-onset S. aureus skin and soft-tissue infection. Empirical use of agents active against community-acquired MRSA is warranted for patients presenting with serious skin and soft-tissue infections.
BACKGROUND: Studies have shown that community-acquired methicillin-resistant Staphylococcus aureus (MRSA) causes S. aureus skin and soft-tissue infection in selected populations. OBJECTIVE: To determine the proportion of infections caused by community-acquired MRSA, the clinical characteristics associated with community-acquired MRSA, and the molecular epidemiology of community-acquired MRSA among persons with community-onset S. aureus skin and soft-tissue infection. DESIGN: Active, prospective laboratory surveillance to identify S. aureus recovered from skin and soft-tissue sources. SETTING: 1000-bed urban hospital and its affiliated outpatient clinics in Atlanta, Georgia. PATIENTS: 384 persons with microbiologically confirmed community-onset S. aureus skin and soft-tissue infection. MEASUREMENTS: Proportion of infections caused by and clinical factors associated with community-acquired MRSA among persons with community-onset S. aureus skin and soft-tissue infection. Pulsed-field gel electrophoresis and antimicrobial susceptibility patterns were used to epidemiologically classify community-onset S. aureus infections. Community-acquired MRSA was defined by MRSA isolates that either demonstrated a USA 300 or USA 400 pulsed-field type or had a susceptibility pattern showing resistance only to beta-lactams and erythromycin (for isolates not available for pulsed-field gel electrophoresis). RESULTS: Community-onset skin and soft-tissue infection due to S. aureus was identified in 389 episodes, with MRSA accounting for 72% (279 of 389 episodes). Among all S. aureus isolates, 63% (244 of 389 isolates) were community-acquired MRSA. Among MRSA isolates, 87% (244 of 279 isolates) were community-acquired MRSA. When analysis was restricted only to MRSA isolates that were available for pulsed-field gel electrophoresis, 91% (159 of 175 isolates) had a pulsed-field type consistent with community-acquired MRSA; of these, 99% (157 of 159 isolates) were the MRSA USA 300 clone. Factors independently associated with community-acquired MRSA infection were black race (prevalence ratio, 1.53 [95% CI, 1.16 to 2.02]), female sex (prevalence ratio, 1.16 [CI, 1.02 to 1.32]), and hospitalization within the previous 12 months (prevalence ratio, 0.80 [CI, 0.66 to 0.97]). Inadequate initial antibiotic therapy was statistically significantly more common among those with community-acquired MRSA (65%) than among those with methicillin-susceptible S. aureus skin and soft-tissue infection (1%). LIMITATIONS: Some MRSA isolates were not available for molecular typing. CONCLUSIONS: The community-acquired MRSA USA 300 clone was the predominant cause of community-onset S. aureus skin and soft-tissue infection. Empirical use of agents active against community-acquired MRSA is warranted for patients presenting with serious skin and soft-tissue infections.
Authors: Adam D Kennedy; Stephen F Porcella; Craig Martens; Adeline R Whitney; Kevin R Braughton; Liang Chen; Carly T Craig; Fred C Tenover; Barry N Kreiswirth; James M Musser; Frank R DeLeo Journal: J Clin Microbiol Date: 2010-10-13 Impact factor: 5.948
Authors: Courtney R Murphy; Lyndsey O Hudson; Brian G Spratt; Victor Quan; Diane Kim; Ellena Peterson; Grace Tan; Kaye Evans; Hildy Meyers; Michele Cheung; Bruce Y Lee; Dana B Mukamel; Mark C Enright; Matthew Whealon; Susan S Huang Journal: Infect Control Hosp Epidemiol Date: 2013-01-23 Impact factor: 3.254
Authors: Gui-Xin He; Michael Landry; Huizhong Chen; Conner Thorpe; Dennis Walsh; Manuel F Varela; Hongmiao Pan Journal: J Med Microbiol Date: 2014-02-28 Impact factor: 2.472
Authors: Ronald N Jones; Angela M Nilius; Bolanle K Akinlade; Lalitagauri M Deshpande; Gerard F Notario Journal: Antimicrob Agents Chemother Date: 2007-06-18 Impact factor: 5.191
Authors: Thomas A Hall; Rangarajan Sampath; Lawrence B Blyn; Raymond Ranken; Cristina Ivy; Rachael Melton; Heather Matthews; Neill White; Feng Li; Vanessa Harpin; David J Ecker; Linda K McDougal; Brandi Limbago; Tracy Ross; Donna M Wolk; Vicki Wysocki; Karen C Carroll Journal: J Clin Microbiol Date: 2009-03-18 Impact factor: 5.948